Nanomed's proprietory FMA technology addresses a number of unmet clinical needs and has applications in many commercial therapeutic areas. Nanomed is currently focusing on two key areas with huge market potential: neuropathicpain management and diabetes managemen It can also be used as a novel tool for product life cycle extension.

For companies looking for a product life-cycle extension or a new drug delivery system, Ｎanomed Devices, Inc. is the strategic partner of choice. Our FMA technology,
patented through 2023, represents the state-of-the-art in drug delivery. This technology is a valuable life-cycle management asset for line-extensions of existing products, as well as for delivery of new biotech drugs such as proteins and peptides. FMA technology can increase the value of our partners' product portfolios through development collaborations and licensing arrangements for a fee or on a risk-sharing basis.